Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
“Now more than ever, it is critical to address inequities in healthcare – so we are incredibly excited to announce the inaugural recipients of our Forward for Health Equity grants,” said
The 2021 Forward for Health Equity grant recipients are:
Emmanual Health Education, Inc.for “The Black Walnut: Sowing Roots for Health Equity and Health Access,” to promote prostate cancer screening and health education around The Black Walnut, a documentary film that examines barriers to care for Black men. University of California, San Franciscofor “Leveraging Technology to Achieve Equity for Men with Prostate Cancer on Androgen Deprivation Therapy,” to develop and test a multilingual, digital personalized lifestyle program to improve care for men with advanced prostate cancer receiving androgen deprivation therapy.
The Center for Black Health & Equityfor “S.I.P. and Share: Women Supporting Women,” to establish a culturally appropriate outreach initiative that addresses knowledge gaps around uterine fibroids, medical mistrust and bias, and access to healthcare. Boston Medical Centerfor “Center of Excellence for Patients with Uterine Fibroids in a Safety- Net Setting,” to create a Fibroid Center to provide multidisciplinary care and implement an innovative, community-partnered patient engagement model at Boston Medical Center.
“Prostate cancer and uterine fibroids disproportionately impact Black Americans, and inequities in healthcare access exacerbate these disparities,” said Reggie Ware, Chief Executive Officer of BlackDoctor.org and member of the grant review committee. “The recipients of the Forward for Health Equity grants have a demonstrated commitment to reducing racial disparities, and I look forward to seeing the impact they achieve in their communities through these innovative initiatives.”
About Myovant Sciences
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. We have one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Our lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
Vice President, Investor Relations
+1 (650) 781-9106
Director, Corporate Communications
+1 (650) 410-3055
Source: Myovant Sciences, Inc.